Synlogic falls as it axes lead program

Synlogic dropped $1.34 (28%) to $3.49 after announcing the discontinuation of its lead program, SYNB1020 for hyperammonemia, based on interim Phase Ib/IIa data showing futility.

CEO Aoife Brennan

Read the full 278 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE